Table 2. Comparation of thyroid hormone levels in different groups of patients with PWS.
| Variables | PWS (n = 23) |
CON (n = 22) |
Boys (n = 12) |
Girls (n = 11) |
DEL (n = 17) |
UPD (n = 6) |
Baseline (n = 9) |
3 months | Baseline (n = 4) |
6 months |
|---|---|---|---|---|---|---|---|---|---|---|
| FT3 (pmol/L) | 5.45 ± 0.95 | 5.88 ± 0.73 | 5.48 ± 1.152 | 5.42 ± 0.73 | 5.41 ± 1.08 | 5.58 ± 0.45 | 5.9 ± 0.75 | 5.77 ± 0.77 | 6.09 ± 0.47 | 6.15 ± 0.55 |
| FT4 (pmol/L) | 12.96 ± 1.92 | 15.91 ± 2.63 | 13.12 ± 2.32 | 12.8 ± 1.44 | 12.73 ± 2 | 13.63 ± 1.63 | 13.03 ± 1.17 | 13.09 ± 2.05 | 14.54 ± 1.87 | 14.24 ± 2.89 |
| TSH (uIU/L) | 2.066 ± 0.96 | 2.07 ± 0.9 | 2.56 ± 1.23 | 1.89 ± 0.64 | 2.01 ± 1.13 | 2.19 ± 0.29* | 1.16 ± 0.39 | 1.45 ± 0.148 | 1.67 ± 0.39 | 1.45 ± 0.148 |
*P < 0.05 (P = 0.0353). Baseline, before growth hormone treatment; PWS, Prader-Willi syndrome; 3 months, 3 months of growth hormone treatment; 6 months, 6 months of growth hormone treatment.